Patients Receiving Anti-Tumour Necrosis Factor Therapies Experience Clinically Important Improvements in Rheumatoid Arthritis Related Fatigue

Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Katie Druce, Gareth Jones, Gary Macfarlane, Neil Basu

Research output: Contribution to journalAbstract

Abstract

Background – Pro-inflammatory cytokines associated with the development and progression of rheumatoid arthritis (RA) have been linked to fatigue. According to randomised controlled trials, anti-TNF therapy results in modest improvements in fatigue, however no such trials have addressed this symptom as the primary research question and therefore have not specifically evaluated response in those presenting with clinically relevant fatigue. This study aimed to determine changes in fatigue and predictors of its improvement, six months after initiating Anti-TNF therapy, in a cohort of RA patients with high baseline fatigue. Methods - Participants recruited to a long-term observational cohort study, the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA), between October 2000 and November 2008, provided information on fatigue using the SF 36 Vitality domain (scored 0-100). The prevalence of high fatigue – SF36 Vitality ≤12.5, defined using the 5th percentile of general population data - was calculated at baseline, and changes in fatigue examined six months subsequently. Changes were considered as a) absolute values and b) improvement from high fatigue to low fatigue (SF36 Vitality >12.5). In those with high baseline fatigue, a comprehensive set of putative predictors of fatigue improvement, were evaluated first individually and then considered within a multivariable logistic regression model. Results - High fatigue at baseline was common (38.8%) among the 6835 subjects (Etanercept n=2441, Infliximab n=1994, Adalimumab n=2400). Of those with high fatigue (n=2652), 70% reported clinically relevant improvements (≥10 SF 36 Vitality units), with a mean improvement of 22.5 units at six month follow up. Further, 66% moved to the “low fatigue” category by follow up and reported a mean change of three times the minimum clinically relevant improvement (32.9 units). Baseline independent predictors of improvement were: female sex (OR 1.3, 95%CI 1.1-1.7), not being unemployed due to ill-health (1.5,1.2-1.7), low disability (1.2,1.0-1.5), rheumatoid factor positive (1.2,1.0-1.4), not using steroids (1.2,1.0-1.5), no history of hypertension (1.4,1.1-1.6) or depression (1.3,1.1-1.5) and good current mental health (1.4,1.2-1.7). Participants who were positive for ≥6 of these variables reported the largest absolute improvement in fatigue, 75% of whom moved to the “low fatigue” category by follow up. Conclusions – These results demonstrate improvement in fatigue is common and substantial, six months after commencing biologics therapy, in those who have clinically relevant fatigue at baseline. Further, in patients with high baseline fatigue, a number of clinical and psycho-social baseline factors can be used to predict the largest improvement, supporting future stratified approaches to RA related fatigue management.
Original languageEnglish
Article number035
JournalRheumatology
Volume53
Issue number Suppl 1
Publication statusPublished - 2014

Fingerprint

Biological Products
Fatigue
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Therapeutics
Logistic Models
Biological Therapy
Rheumatoid Factor

Cite this

@article{38fd846f4c08498dbf258cd941809e25,
title = "Patients Receiving Anti-Tumour Necrosis Factor Therapies Experience Clinically Important Improvements in Rheumatoid Arthritis Related Fatigue: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis",
abstract = "Background – Pro-inflammatory cytokines associated with the development and progression of rheumatoid arthritis (RA) have been linked to fatigue. According to randomised controlled trials, anti-TNF therapy results in modest improvements in fatigue, however no such trials have addressed this symptom as the primary research question and therefore have not specifically evaluated response in those presenting with clinically relevant fatigue. This study aimed to determine changes in fatigue and predictors of its improvement, six months after initiating Anti-TNF therapy, in a cohort of RA patients with high baseline fatigue. Methods - Participants recruited to a long-term observational cohort study, the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA), between October 2000 and November 2008, provided information on fatigue using the SF 36 Vitality domain (scored 0-100). The prevalence of high fatigue – SF36 Vitality ≤12.5, defined using the 5th percentile of general population data - was calculated at baseline, and changes in fatigue examined six months subsequently. Changes were considered as a) absolute values and b) improvement from high fatigue to low fatigue (SF36 Vitality >12.5). In those with high baseline fatigue, a comprehensive set of putative predictors of fatigue improvement, were evaluated first individually and then considered within a multivariable logistic regression model. Results - High fatigue at baseline was common (38.8{\%}) among the 6835 subjects (Etanercept n=2441, Infliximab n=1994, Adalimumab n=2400). Of those with high fatigue (n=2652), 70{\%} reported clinically relevant improvements (≥10 SF 36 Vitality units), with a mean improvement of 22.5 units at six month follow up. Further, 66{\%} moved to the “low fatigue” category by follow up and reported a mean change of three times the minimum clinically relevant improvement (32.9 units). Baseline independent predictors of improvement were: female sex (OR 1.3, 95{\%}CI 1.1-1.7), not being unemployed due to ill-health (1.5,1.2-1.7), low disability (1.2,1.0-1.5), rheumatoid factor positive (1.2,1.0-1.4), not using steroids (1.2,1.0-1.5), no history of hypertension (1.4,1.1-1.6) or depression (1.3,1.1-1.5) and good current mental health (1.4,1.2-1.7). Participants who were positive for ≥6 of these variables reported the largest absolute improvement in fatigue, 75{\%} of whom moved to the “low fatigue” category by follow up. Conclusions – These results demonstrate improvement in fatigue is common and substantial, six months after commencing biologics therapy, in those who have clinically relevant fatigue at baseline. Further, in patients with high baseline fatigue, a number of clinical and psycho-social baseline factors can be used to predict the largest improvement, supporting future stratified approaches to RA related fatigue management.",
author = "Katie Druce and Gareth Jones and Gary Macfarlane and Neil Basu",
year = "2014",
language = "English",
volume = "53",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "OXFORD UNIV PRESS INC",
number = "Suppl 1",

}

TY - JOUR

T1 - Patients Receiving Anti-Tumour Necrosis Factor Therapies Experience Clinically Important Improvements in Rheumatoid Arthritis Related Fatigue

T2 - Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

AU - Druce, Katie

AU - Jones, Gareth

AU - Macfarlane, Gary

AU - Basu, Neil

PY - 2014

Y1 - 2014

N2 - Background – Pro-inflammatory cytokines associated with the development and progression of rheumatoid arthritis (RA) have been linked to fatigue. According to randomised controlled trials, anti-TNF therapy results in modest improvements in fatigue, however no such trials have addressed this symptom as the primary research question and therefore have not specifically evaluated response in those presenting with clinically relevant fatigue. This study aimed to determine changes in fatigue and predictors of its improvement, six months after initiating Anti-TNF therapy, in a cohort of RA patients with high baseline fatigue. Methods - Participants recruited to a long-term observational cohort study, the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA), between October 2000 and November 2008, provided information on fatigue using the SF 36 Vitality domain (scored 0-100). The prevalence of high fatigue – SF36 Vitality ≤12.5, defined using the 5th percentile of general population data - was calculated at baseline, and changes in fatigue examined six months subsequently. Changes were considered as a) absolute values and b) improvement from high fatigue to low fatigue (SF36 Vitality >12.5). In those with high baseline fatigue, a comprehensive set of putative predictors of fatigue improvement, were evaluated first individually and then considered within a multivariable logistic regression model. Results - High fatigue at baseline was common (38.8%) among the 6835 subjects (Etanercept n=2441, Infliximab n=1994, Adalimumab n=2400). Of those with high fatigue (n=2652), 70% reported clinically relevant improvements (≥10 SF 36 Vitality units), with a mean improvement of 22.5 units at six month follow up. Further, 66% moved to the “low fatigue” category by follow up and reported a mean change of three times the minimum clinically relevant improvement (32.9 units). Baseline independent predictors of improvement were: female sex (OR 1.3, 95%CI 1.1-1.7), not being unemployed due to ill-health (1.5,1.2-1.7), low disability (1.2,1.0-1.5), rheumatoid factor positive (1.2,1.0-1.4), not using steroids (1.2,1.0-1.5), no history of hypertension (1.4,1.1-1.6) or depression (1.3,1.1-1.5) and good current mental health (1.4,1.2-1.7). Participants who were positive for ≥6 of these variables reported the largest absolute improvement in fatigue, 75% of whom moved to the “low fatigue” category by follow up. Conclusions – These results demonstrate improvement in fatigue is common and substantial, six months after commencing biologics therapy, in those who have clinically relevant fatigue at baseline. Further, in patients with high baseline fatigue, a number of clinical and psycho-social baseline factors can be used to predict the largest improvement, supporting future stratified approaches to RA related fatigue management.

AB - Background – Pro-inflammatory cytokines associated with the development and progression of rheumatoid arthritis (RA) have been linked to fatigue. According to randomised controlled trials, anti-TNF therapy results in modest improvements in fatigue, however no such trials have addressed this symptom as the primary research question and therefore have not specifically evaluated response in those presenting with clinically relevant fatigue. This study aimed to determine changes in fatigue and predictors of its improvement, six months after initiating Anti-TNF therapy, in a cohort of RA patients with high baseline fatigue. Methods - Participants recruited to a long-term observational cohort study, the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA), between October 2000 and November 2008, provided information on fatigue using the SF 36 Vitality domain (scored 0-100). The prevalence of high fatigue – SF36 Vitality ≤12.5, defined using the 5th percentile of general population data - was calculated at baseline, and changes in fatigue examined six months subsequently. Changes were considered as a) absolute values and b) improvement from high fatigue to low fatigue (SF36 Vitality >12.5). In those with high baseline fatigue, a comprehensive set of putative predictors of fatigue improvement, were evaluated first individually and then considered within a multivariable logistic regression model. Results - High fatigue at baseline was common (38.8%) among the 6835 subjects (Etanercept n=2441, Infliximab n=1994, Adalimumab n=2400). Of those with high fatigue (n=2652), 70% reported clinically relevant improvements (≥10 SF 36 Vitality units), with a mean improvement of 22.5 units at six month follow up. Further, 66% moved to the “low fatigue” category by follow up and reported a mean change of three times the minimum clinically relevant improvement (32.9 units). Baseline independent predictors of improvement were: female sex (OR 1.3, 95%CI 1.1-1.7), not being unemployed due to ill-health (1.5,1.2-1.7), low disability (1.2,1.0-1.5), rheumatoid factor positive (1.2,1.0-1.4), not using steroids (1.2,1.0-1.5), no history of hypertension (1.4,1.1-1.6) or depression (1.3,1.1-1.5) and good current mental health (1.4,1.2-1.7). Participants who were positive for ≥6 of these variables reported the largest absolute improvement in fatigue, 75% of whom moved to the “low fatigue” category by follow up. Conclusions – These results demonstrate improvement in fatigue is common and substantial, six months after commencing biologics therapy, in those who have clinically relevant fatigue at baseline. Further, in patients with high baseline fatigue, a number of clinical and psycho-social baseline factors can be used to predict the largest improvement, supporting future stratified approaches to RA related fatigue management.

M3 - Abstract

VL - 53

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - Suppl 1

M1 - 035

ER -